Literature DB >> 26341365

Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.

Daniela Perani1,2,3, Chiara Cerami4,5,6, Silvia Paola Caminiti4,5, Roberto Santangelo7, Elisabetta Coppi7, Laura Ferrari7, Patrizia Pinto8, Gabriella Passerini9, Andrea Falini4,5,10, Sandro Iannaccone6, Stefano Francesco Cappa5,11, Giancarlo Comi4,7, Luigi Gianolli12, Giuseppe Magnani13.   

Abstract

PURPOSE: The aim of this study was to evaluate the supportive role of molecular and structural biomarkers (CSF protein levels, FDG PET and MRI) in the early differential diagnosis of dementia in a large sample of patients with neurodegenerative dementia, and in determining the risk of disease progression in subjects with mild cognitive impairment (MCI).
METHODS: We evaluated the supportive role of CSF Aβ42, t-Tau, p-Tau levels, conventional brain MRI and visual assessment of FDG PET SPM t-maps in the early diagnosis of dementia and the evaluation of MCI progression.
RESULTS: Diagnosis based on molecular biomarkers showed the best fit with the final diagnosis at a long follow-up. FDG PET SPM t-maps had the highest diagnostic accuracy in Alzheimer's disease and in the differential diagnosis of non-Alzheimer's disease dementias. The p-tau/Aβ42 ratio was the only CSF biomarker providing a significant classification rate for Alzheimer's disease. An Alzheimer's disease-positive metabolic pattern as shown by FDG PET SPM in MCI was the best predictor of conversion to Alzheimer's disease.
CONCLUSION: In this clinical setting, FDG PET SPM t-maps and the p-tau/Aβ42 ratio improved clinical diagnostic accuracy, supporting the importance of these biomarkers in the emerging diagnostic criteria for Alzheimer's disease dementia. FDG PET using SPM t-maps had the highest predictive value by identifying hypometabolic patterns in different neurodegenerative dementias and normal brain metabolism in MCI, confirming its additional crucial exclusionary role.

Entities:  

Keywords:  Alzheimer’s Disease; Biomarkers; Clinical setting; Dementia diagnosis; Mild Cognitive Impairment

Mesh:

Substances:

Year:  2015        PMID: 26341365     DOI: 10.1007/s00259-015-3170-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  56 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.

Authors:  Akiyoshi Morinaga; Kenjiro Ono; Tokuhei Ikeda; Yoshihisa Ikeda; Keisuke Shima; Moeko Noguchi-Shinohara; Miharu Samuraki; Daisuke Yanase; Mitsuhiro Yoshita; Kazuo Iwasa; Ichiro Mastunari; Masahito Yamada
Journal:  Dement Geriatr Cogn Disord       Date:  2010-09-22       Impact factor: 2.959

Review 3.  Functional neuroimaging of cognition.

Authors:  Daniela Perani
Journal:  Handb Clin Neurol       Date:  2008

4.  Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.

Authors:  Il Han Choo; Ruiqing Ni; Michael Schöll; Anders Wall; Ove Almkvist; Agneta Nordberg
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

6.  Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Authors:  K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

7.  Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.

Authors:  Chiara Cerami; Pasquale Anthony Della Rosa; Giuseppe Magnani; Roberto Santangelo; Alessandra Marcone; Stefano F Cappa; Daniela Perani
Journal:  Neuroimage Clin       Date:  2014-12-05       Impact factor: 4.881

8.  Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.

Authors:  Joseph E Gaugler; Haya Ascher-Svanum; David L Roth; Tolulope Fafowora; Andrew Siderowf; Thomas G Beach
Journal:  BMC Geriatr       Date:  2013-12-19       Impact factor: 3.921

9.  Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting.

Authors:  Daniela Perani; Pasquale Anthony Della Rosa; Chiara Cerami; Francesca Gallivanone; Federico Fallanca; Emilia Giovanna Vanoli; Andrea Panzacchi; Flavio Nobili; Sabina Pappatà; Alessandra Marcone; Valentina Garibotto; Isabella Castiglioni; Giuseppe Magnani; Stefano F Cappa; Luigi Gianolli
Journal:  Neuroimage Clin       Date:  2014-10-24       Impact factor: 4.881

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  33 in total

Review 1.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

Review 2.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 3.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

4.  Validation of 18F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners.

Authors:  Luca Presotto; Tommaso Ballarini; Silvia Paola Caminiti; Valentino Bettinardi; Luigi Gianolli; Daniela Perani
Journal:  Neuroinformatics       Date:  2017-04

5.  Metabolic connectomics targeting brain pathology in dementia with Lewy bodies.

Authors:  Silvia P Caminiti; Marco Tettamanti; Arianna Sala; Luca Presotto; Sandro Iannaccone; Stefano F Cappa; Giuseppe Magnani; Daniela Perani
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

6.  Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.

Authors:  Artur Martins Coutinho; Geraldo F Busatto; Fábio Henrique de Gobbi Porto; Daniele de Paula Faria; Carla Rachel Ono; Alexandre Teles Garcez; Paula Squarzoni; Fábio Luiz de Souza Duran; Maira Okada de Oliveira; Eduardo Sturzeneker Tres; Sonia Maria Dozzi Brucki; Orestes Vicente Forlenza; Ricardo Nitrini; Carlos Alberto Buchpiguel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-13       Impact factor: 9.236

7.  Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.

Authors:  Arianna Sala; Leonardo Iaccarino; Piercarlo Fania; Emilia G Vanoli; Federico Fallanca; Caterina Pagnini; Chiara Cerami; Andrea Calvo; Antonio Canosa; Marco Pagani; Adriano Chiò; Angelina Cistaro; Daniela Perani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-07       Impact factor: 9.236

8.  Brain metabolic signatures across the Alzheimer's disease spectrum.

Authors:  Arianna Sala; Camilla Caprioglio; Roberto Santangelo; Emilia Giovanna Vanoli; Sandro Iannaccone; Giuseppe Magnani; Daniela Perani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-07       Impact factor: 9.236

9.  Gender differences in healthy aging and Alzheimer's Dementia: A 18 F-FDG-PET study of brain and cognitive reserve.

Authors:  Maura Malpetti; Tommaso Ballarini; Luca Presotto; Valentina Garibotto; Marco Tettamanti; Daniela Perani
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

10.  FDG-PET patterns associated with underlying pathology in corticobasal syndrome.

Authors:  Matteo Pardini; Edward D Huey; Salvatore Spina; William C Kreisl; Silvia Morbelli; Eric M Wassermann; Flavio Nobili; Bernardino Ghetti; Jordan Grafman
Journal:  Neurology       Date:  2019-01-30       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.